Literature DB >> 72140

Malignant diseases among patients with multiple sclerosis.

J Palo, J Duchesne, J Wikström.   

Abstract

The frequency of malignant diseases among 1866 living and 340 deceased multiple sclerosis (MS) patients was investigated in Finland. The study revealed a low prevalence (0.64%) and mortality (0.07%) rate of cancer among MS patients. The difference between MS patients and general population was significant. The highest rate was found in the group from 40 to 49 years while in the general population the rate of cancer among MS patients tended to fall after the age of 50. The possible role of selenium, one of the antioxidants in the pathogenesis of MS and cancer, is discussed because recent data have shown a very high negative correlation between selenium and cancer death rates.

Entities:  

Mesh：

Year:  1977        PMID： 72140     DOI： 10.1007/BF00313623

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  13 in total

1.  Cancer in Finland 1953-1970: incidence, mortality, prevalence.

Authors:  L Teppo; M Hakama; T Hakulinen; M Lehtonen; E Saxén
Journal:  Acta Pathol Microbiol Scand Suppl       Date:  1975

2.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

3.  [Statistical studies of multiple sclerosis based on 947 autopsy records].

Authors:  M MARETSCHEK; G SCHALTENBRAND; P SEIBERT
Journal:  Dtsch Z Nervenheilkd       Date:  1954

4.  Studies on the clustering of multiple sclerosis in Finland I: Comparison between the domiciles and places of birth in selected subpopulations.

Authors:  J Wikström; J Palo
Journal:  Acta Neurol Scand       Date:  1975-02       Impact factor: 3.209

5.  A unifying biochemical theory of cancer, senescence and maximal life span.

Authors:  J Duchesne
Journal:  J Theor Biol       Date:  1977-05-07       Impact factor: 2.691

6.  Nutritional muscular dystrophy and human myocardial infarction.

Authors:  T W Anderson
Journal:  Lancet       Date:  1973-08-11       Impact factor: 79.321

7.  Letter: Epidemiology of nutritional muscular dystrophy and multiple sclerosis.

Authors:  J Palo; J Wikström; E Kivalo
Journal:  Lancet       Date:  1973-10-13       Impact factor: 79.321

8.  Possible protective effect of selenium against human cancer.

Authors:  R J Shamberger; D V Frost
Journal:  Can Med Assoc J       Date:  1969-04-12       Impact factor: 8.262

9.  The epidemiology of multiple sclerosis and tuberculosis in Finland. A study based on mortality statistics.

Authors:  J Wikström
Journal:  Acta Neurol Scand       Date:  1975-09       Impact factor: 3.209

10.  Selenium, vitamin E and copper in multiple sclerosis.

Authors:  J Wikström; T Westermarck; J Palo
Journal:  Acta Neurol Scand       Date:  1976-09       Impact factor: 3.209
View more
  14 in total

1.  Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.

Authors:  Daniela A Bota; Daniela Alexandru-Abrams; Chrystel Pretto; Florence M Hofman; Thomas C Chen; Beverly Fu; Jose A Carrillo; Virgil Ejc Schijns; Apostolos Stathopoulos
Journal:  Perm J       Date:  2015-03-01

2.  Studies on the geographic clustering of multiple sclerosis and optic neuritis in Finland.

Authors:  J Wikström; J Palo
Journal:  J Neurol       Date:  1976-08-06       Impact factor: 4.849

3.  Cancer and multiple sclerosis in the era of disease-modifying treatments.

Authors:  Christine Lebrun; Patrick Vermersch; David Brassat; Gilles Defer; Lucien Rumbach; Pierre Clavelou; Marc Debouverie; Jérôme de Seze; Sandrine Wiertlevsky; Olivier Heinzlef; Ayman Tourbah; Agnes Fromont; Marc Frenay
Journal:  J Neurol       Date:  2011-02-04       Impact factor: 4.849

4.  Multiple sclerosis and malignant neoplasms in the central nervous system: a clinical anatomical report of three cases.

Authors:  F W Spaar; J Wikström
Journal:  J Neurol       Date:  1978-04-14       Impact factor: 4.849

5.  Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data.

Authors:  Gary Bloomgren; Bjørn Sperling; Kimberly Cushing; Madé Wenten
Journal:  Ther Clin Risk Manag       Date:  2012-06-20       Impact factor: 2.423

Review 6.  The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy.

Authors:  Peter O Behan; Abhijit Chaudhuri
Journal:  Inflammopharmacology       Date:  2010-09-24       Impact factor: 5.093

Review 7.  A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis.

Authors:  Ruth Ann Marrie; Nadia Reider; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Gary Cutter; Stephen Reingold; Per Soelberg Sorensen
Journal:  Mult Scler       Date:  2014-12-22       Impact factor: 6.312

Review 8.  A systematic review of the incidence and prevalence of cancer in multiple sclerosis.

Authors:  Ruth Ann Marrie; Nadia Reider; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Per Soelberg Sorensen; Stephen C Reingold; Gary Cutter
Journal:  Mult Scler       Date:  2014-12-22       Impact factor: 6.312

Review 9.  A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview.

Authors:  Ruth Ann Marrie; Jeffrey Cohen; Olaf Stuve; Maria Trojano; Per Soelberg Sørensen; Stephen Reingold; Gary Cutter; Nadia Reider
Journal:  Mult Scler       Date:  2015-01-26       Impact factor: 6.312

10.  Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis.

Authors:  Pouya Khankhanian; Wendy Cozen; Daniel S Himmelstein; Lohith Madireddy; Lennox Din; Anke van den Berg; Takuya Matsushita; Sally L Glaser; Jayaji M Moré; Karin E Smedby; Sergio E Baranzini; Thomas M Mack; Antoine Lizée; Silvia de Sanjosé; Pierre-Antoine Gourraud; Alexandra Nieters; Stephen L Hauser; Pierluigi Cocco; Marc Maynadié; Lenka Foretová; Anthony Staines; Manon Delahaye-Sourdeix; Dalin Li; Smita Bhatia; Mads Melbye; Kenan Onel; Ruth Jarrett; James D McKay; Jorge R Oksenberg; Henrik Hjalgrim
Journal:  Int J Epidemiol       Date:  2016-03-12       Impact factor: 7.196
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.